Italia markets close in 3 hours 7 minutes

Sotera Health Company (SHC)

NasdaqGS - NasdaqGS Prezzo in tempo reale. Valuta in USD.
Aggiungi a portafoglio
20,60-0,10 (-0,48%)
Alla chiusura: 04:00PM EST
19,29 -1,31 (-6,36%)
Dopo ore: 05:47PM EST
Schermo intero
I prezzi di scambio non provengono da tutti i mercati
Chiusura precedente20,70
Aperto20,67
Denaro0,00 x 1800
Lettera0,00 x 900
Min-Max giorno20,35 - 20,99
Intervallo di 52 settimane20,35 - 30,38
Volume301.810
Media Volume704.393
Capitalizzazione5,828B
Beta (5 anni mensile)N/D
Rapporto PE (ttm)151,47
EPS (ttm)0,14
Prossima data utili01 mar 2022
Rendimento e dividendo (forward)N/D (N/D)
Data ex dividendoN/D
Stima target 1A31,67
  • GlobeNewswire

    Sotera Health Chairman and CEO Presents at 40th Annual J.P. Morgan Healthcare Virtual Conference

    CLEVELAND, Jan. 11, 2022 (GLOBE NEWSWIRE) -- Sotera Health Company (“Sotera Health” or the “Company”) (NASDAQ: SHC), a leading global provider of mission-critical end-to-end sterilization solutions, lab testing and advisory services for the healthcare industry, today is providing an update on the Company’s accomplishments and key growth drivers, as well as the current market dynamics related to its businesses. At the 40th Annual J.P. Morgan Healthcare Conference, Chairman and Chief Executive Off

  • GlobeNewswire

    Sotera Health to Present at the Virtual 40th Annual J.P. Morgan Healthcare Conference

    CLEVELAND, Jan. 03, 2022 (GLOBE NEWSWIRE) -- Sotera Health Company (“Sotera Health” or the “Company”) (NASDAQ: SHC), a leading global provider of mission-critical end-to-end sterilization solutions, lab testing and advisory services for the healthcare industry, today announced that Chairman and CEO Michael B. Petras, Jr. will present at the 40th Annual J.P. Morgan Healthcare Conference on Tuesday, January 11, 2022 at 7:30 am Eastern. In his presentation, Mr. Petras will provide an update on Sote

  • GlobeNewswire

    Sotera Health Reports Third-Quarter and Year-to-Date 2021 Results

    Q3 2021 net revenues of $226 million increased 13%, compared to Q3 2020Q3 2021 net income of $27 million or $0.10 per diluted share, compared to net income of $0.01 million or $0.00 per diluted share in Q3 2020Q3 2021 Adjusted EBITDA of $117 million increased 16%, compared to Q3 2020Q3 2021 Adjusted EPS of $0.21 improved $0.12 compared to Q3 2020September 30, 2021 total debt of $1.8 billion and total net debt of $1.7 billion; net leverage ratio improved to 3.6xNarrowing full-year 2021 revenue gr